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Summary 
Background 
The standard busulfan–cyclophosphamide myeloablative conditioning regimen is associated with 
substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who 
are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus 
fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment 
with busulfan plus cyclophosphamide as a preparative regimen in these patients. 
Methods 
We did an open-label, multicentre, randomised, phase 3 trial for patients with acute myeloid 
leukaemia at 25 hospital transplant centres in Italy and one in Israel. Eligible patients were aged 40–
65 years, had an Eastern Cooperative Oncology Group performance status less than 3, and were in 
complete remission. Patients were randomly assigned 1:1 to receive intravenous busulfan plus 
cyclophosphamide or busulfan plus fludarabine. Treatment allocations were not masked to 
investigators or patients. Randomisation was done centrally via a dedicated web-based system using 
remote data entry, with patients stratified by donor type and complete remission status. Patients 
allocated to busulfan plus cyclophosphamide received intravenous busulfan 0·8 mg/kg four times 
per day during 2 h infusions for four consecutive days (16 doses from days −9 through −6; total 
dose 12·8 mg/kg) and cyclophosphamide at 60 mg/kg per day for two consecutive days (on days −4 
and −3; total dose 120 mg/kg). Patients allocated to busulfan plus fludarabine received the same 
dose of intravenous busulfan (from days −6 through −3) and fludarabine at 40 mg/m2 per day for 
four consecutive days (from days −6 through −3; total dose 160 mg/m2). The primary endpoint was 
1-year non-relapse mortality, which was assessed on an intention-to-treat basis; safety outcomes 
were assessed in the per-protocol population. This trial has been completed and is registered with 
ClinicalTrials.gov, number NCT01191957. 
Findings 
Between Jan 3, 2008, and Dec 20, 2012, we enrolled and randomly assigned 252 patients to receive 
busulfan plus cyclophosphamide (n=125) or busulfan plus fludarabine (n=127). Median follow-up 
was 27·5 months (IQR 9·8–44·3). 1-year non-relapse mortality was 17·2% (95% CI 11·6–25·4) in 
the busulfan plus cyclophosphamide group and 7·9% (4·3–14·3) in the busulfan plus fludarabine 
group (Gray's test p=0·026). The most frequently reported grade 3 or higher adverse events were 
gastrointestinal events (28 [23%] of 121 patients in the busulfan plus cyclophosphamide group and 
26 [21%] of 124 patients in the busulfan plus fludarabine group) and infections (21 [17%] patients 
in the busulfan plus cyclophosphamide group and 13 [10%] patients in the busulfan plus fludarabine 
group had at least one such event). 
Interpretation 
In older patients with acute myeloid leukaemia, the myeloablative busulfan plus fludarabine 
conditioning regimen is associated with lower transplant-related mortality than busulfan plus 
cyclophosphamide, but retains potent antileukaemic activity. Accordingly, this regimen should be 
regarded as standard of care during the planning of allogeneic transplants for such patients. 
Funding 
Agenzia Italiana del Farmaco. 
Introduction 
Allogeneic stem-cell transplantation is the most effective way to control leukaemia relapse for 
patients with acute myeloid leukaemia. In younger adults (ie, aged 18–40 years) with intermediate-
risk or poor-risk acute myeloid leukaemia, allogeneic stem-cell transplant after myeloablative 
conditioning should be regarded as the treatment of choice for patients in their first complete 
remission.
1
 Whether selection of transplant candidates can be improved by prediction of non-
relapse mortality remains an issue under active investigation.
2 and 3
 In younger patients (ie, aged 18–
40 years) the combination of a myeloablative dose of intravenous busulfan with cyclophosphamide 
is a standard preparative regimen, which compares favourably with the combination of 
cyclophosphamide and ablative doses (usually 12 Gy) of total body irradiation.
4, 5 and 6
 However, 
myeloablative regimens are associated with substantial treatment-related toxicity in patients older 
than 40 years. In the HOVON-SAKK meta-analysis of several donor versus no donor studies,
7
 no 
advantage was detected for patients older than 40 years compared with younger patients.
7
 In the late 
1990s, non-relapse mortality in older patients was the major driver for the development of reduced 
intensity conditioning (RIC) regimens, which aimed to minimise regimen-related toxicity while 
securing engraftment and providing a platform for the graft-versus-leukaemia effect.
8 and 9
 During 
the past two decades, the proportion of allogeneic grafts performed after RIC regimens has grown 
rapidly, resulting in a substantial rise in the median age of patients undergoing transplantation. 
However, after this initial enthusiasm, it was reported that RIC regimens were associated with a 
significantly increased risk of relapse.
10
 Overall, the benefit of reduced non-relapse mortality that 
RIC regimens provide is counterbalanced by an increased risk of relapse.
11
 
Panel.  
Research in context 
Evidence before this study 
We searched PubMed for articles that were published in English before June 1, 2015, and about 
conditioning regimens for allogeneic haemopoietic cell transplantation in acute myeloid leukaemia 
using the keywords “acute myeloid leukemia (AML)”, “allogeneic transplantation”, and 
“conditioning regimen”. In younger adults with intermediate or poor-risk acute myeloid leukaemia, 
allogeneic stem-cell transplant following myeloablative conditioning is the consolidation treatment 
of choice for patients in remission. Before we started our trial, the HOVON-SAKK meta-analysis of 
several donor versus no donor studies indicated no survival advantage for patients with acute 
myeloid leukaemia who had a donor but were aged older than 40 years compared with younger 
patients. With the intent to reduce the high non-relapse mortality, which represents the major reason 
for transplant failure, several reduced intensity conditioning regimens have been proposed to 
minimise transplant toxicity. Although the feasibility of transplants in older patients using these 
programmes has been confirmed by many phase 2 studies, concerns have been raised about a 
significantly increased risk of relapse. At the time we designed our study, no abstracts or 
manuscripts had been reported with results from randomised trials comparing myeloablative with 
reduced intensity or reduced toxicity conditioning regimens in patients with acute myeloid 
leukaemia. For this reason we planned a randomised comparison between the standard 
myeloablative programme based on intravenous busulfan and cyclophosphamide and a reduced 
toxicity regimen based on the same myeloablative dose of busulfan and fludarabine. The latter 
regimen has been proposed to be similarly effective to busulfan plus cyclophosphamide, with a 
remarkably good toxicity profile, low non-relapse mortality, and a low relapse rate in older patients 
with acute myeloid leukaemia. 
Added value of this study 
Two randomised trials comparing the same conditioning regimens in younger patients have been 
reported and provided conflicting results regarding the efficacy and toxicity of busulfan plus 
fludarabine. Additionally, a randomised trial (prematurely stopped because of slow accrual of 
patients) to compare reduced intensity total body irradiation plus fludarabine with standard total 
body irradiation plus cyclophosphamide did not identify any significant difference in terms of non-
relapse mortality, relapse incidence, disease-free survival, or overall survival in patients with acute 
myeloid leukaemia with a median age of 45 years. To our knowledge, our study is the first 
randomised trial specifically designed to compare these regimens in older patients with acute 
myeloid leukaemia undergoing transplantation in their first or subsequent haematological remission 
with a related or unrelated donor. Non-relapse mortality was significantly reduced with the busulfan 
plus fludarabine regimen compared with the busulfan plus cyclophosphamide regimen in all 
subgroups independent of patient age and sex, donor type, and acute myeloid leukaemia risk 
biology (European Leukemia Network score). This is probably because of reduced organ toxicity in 
the busulfan plus fludarabine group. The reduced non-relapse mortality did not come at the cost of 
an increased incidence of relapse. 
Implications of all the available evidence 
In older patients with acute myeloid leukaemia, the reduced toxicity of busulfan plus fludarabine, 
although still myeloablative, conferred low transplant-related mortality while preserving potent 
antileukaemic activity. Accordingly, we recommend that it should be considered as a standard of 
care in the planning of an allogeneic transplant for such patients. 
Conditioning regimens need to be developed that will retain the antileukaemic activity of 
myeloablative conditioning, while reducing the transplant-related toxicity to the level of reduced 
RIC regimens: these programmes are tentatively referred to as reduced toxicity regimens.
12
 One 
such regimen is based on the combination of a myeloablative dose of intravenous busulfan (12·8 
mg/kg or equivalent) with fludarabine (160 mg/m
2
 or similar), which has been reported to be 
effective for patients with acute myeloid leukaemia.
13
 In a retrospective analysis,
14
 the busulfan plus 
fludarabine regimen was associated with reduced non-relapse mortality, shortened time to 
engraftment, and reduced incidence of acute and chronic graft-versus-host disease compared with 
busulfan plus cyclophosphamide. An increased frequency of relapse with the busulfan plus 
fludarabine regimen has been noted in some,
15
 but not all, studies.
14
 However, all of these analyses 
have been retrospective, and whether the busulfan plus fludarabine regimen represents an 
improvement for patients with acute myeloid leukaemia is not clear. Two randomised trials 
investigating these conditioning regimens in younger patients have been reported. In the first,
16
 
which was done in a patient population that included patients with acute myeloid leukaemia, acute 
lymphoblastic leukaemia, and other haematological malignancies, the busulfan plus fludarabine 
regimen did not prove to be a suitable replacement for busulfan plus cyclophosphamide because a 
higher incidence of relapse was noted in the busulfan plus fludarabine regimen compared with the 
busulfan plus cyclophosphamide regimen. Conversely, in another trial in young patients with acute 
myeloid leukaemia, the busulfan plus fludarabine regimen was reported to be associated with less 
toxicity than the busulfan plus cyclophosphamide regimen, but had similar antileukaemic activity.
17
 
In view of this conflicting evidence, we did a randomised trial to compare the standard 
myeloablative busulfan plus cyclophosphamide regimen with the reduced toxicity busulfan plus 
fludarabine regimen for older patients with acute myeloid leukaemia undergoing allogeneic stem-
cell transplantation. 
Methods 
Study design and participants 
This study was an open-label, multicentre, randomised, phase 3 trial done in 25 hospital transplant 
centres in Italy and one in Israel (appendix), coordinated by the Gruppo Italiano Trapianto di 
Midollo Osseo e Terapie Cellulari (GITMO) network. Patients were eligible if they had a diagnosis 
of acute myeloid leukaemia, were in their first, second, or further complete haematological 
remission (as established by morphological assessment of the bone marrow), were aged 40–65 
years, had an Eastern Cooperative Oncology Group performance status less than 3, and had an 
HLA-identical matched related or matched unrelated donor as defined by molecular high-resolution 
typing (four digits) of the HLA gene loci for class I (HLA-A, HLA-B, and HLA-C) and class II 
(DRB1). If no completely identical donor could be identified according to the minimal degree of 
matching established by the Italian Bone Marrow Donor Registry, one antigen or allele disparity 
(class I) or one allele disparity (class II) between the patient and donor was acceptable. Estimated 
survival of patients at enrolment was more than 3 months. We excluded patients if they were in first 
complete remission with t(15;17)(q22;q12) or PML/RARα-positive acute promyelocytic leukaemia, 
or t(8;21)(q22;q22)-positive and inv(16) or t(16;16)(p13;q22)-positive acute myeloid leukaemia 
with white blood cell counts less than 20 × 109 cells per L at diagnosis and additional adverse 
cytogenetic abnormalities. We also excluded previously transplanted patients and patients with 
uncontrolled infections or severe cardiovascular, renal, hepatic, pulmonary, or psychiatric disorders 
or any disorder that compromised the ability to give truly informed consent for participation in this 
study. Patients with another progressive malignant disease or a history of other malignancies within 
2 years before study entry were also excluded. After assessment of complete remission, no 
additional chemotherapy could be given before the start of the conditioning regimen. 
We did the study in accordance with the International Conference on Harmonization for Good 
Clinical Practice and the appropriate regulatory requirements. The study was approved by the ethics 
committees of the participating centres and all patients and donors provided written informed 
consent before inclusion. The trial protocol was in accordance with the Declaration of Helsinki and 
is available online. 
Randomisation and masking 
Patients were randomly assigned (1:1) with a stratified biased coin algorithm with a variable block 
size strategy to receive either the busulfan plus cyclophosphamide or the busulfan plus fludarabine 
conditioning regimen. Randomisation was centralised at the Fondazione Mario Negri Sud (Santa 
Maria Imbaro, Chieti, Italy) and was done via a dedicated web-based system with remote data entry. 
Patients were stratified by donor type (matched related donor vs matched unrelated donor) and 
remission status (first complete remission vs second or further complete remission). Treatment 
allocations were not masked to the investigators, participants, those assessing outcomes, or those 
analysing the data. 
Procedures 
The standard treatment group received a myeloablative combination of intravenous busulfan 
(Laboratoires Pierre Fabre, Boulogne, France) 0·8 mg/kg four times per day during 2 h infusions for 
four consecutive days (16 doses from day −9 through day −6; total dose of 12·8 mg/kg) with 
cyclophosphamide 60 mg/kg per day for two consecutive days (on days −4 and −3; total dose of 
120 mg/kg). The experimental group received the same myeloablative dose of intravenous busulfan 
(from day −6 through day −3) combined with fludarabine 40 mg/m2 per day for four consecutive 
days (from day −6 through day −3) for a total dose of 160 mg/m2. All patients received fixed doses 
of busulfan and no pharmacokinetic monitoring was done. No dose reductions or interruptions were 
allowed. On day 0, patients received either bone marrow cells or granulocyte-colony stimulating 
factor (G-CSF)-mobilised peripheral blood progenitor cells in their transplantation. 
Prophylaxis for graft-versus-host disease was based on conventional ciclosporin A 1·5 mg/kg twice 
per day by short intravenous infusion starting on day −1 before transplant (to reach target trough 
level concentration 200 ng/mL or higher) and methotrexate 15 mg/m
2
 given intravenously on day 1, 
and subsequently at 10 mg/m
2
 intravenously on days 3, 6, and 11. Patients in both treatment groups 
who received stem cells from unrelated donors were treated with anti-thymocyte immunoglobulin 
(Genzyme, Cambridge, MA, USA) 0·5 mg/kg intravenously on day −3 and 2·0 mg/kg intravenously 
on day −2 and, if the donor was identical, 2·5 mg/kg on day −1. In cases with one antigen or allele 
disparity (class I) or one allele disparity (class II) between donor and recipient, the total dose of 
anti-thymocyte immunoglobulin could be increased up to 7·5 mg/kg. 
After transplantation, patients were followed up until the end of the study. The main outcome data 
were collected and the main assessments of adverse events were done on days 30, 60, 100, and 180, 
then at 1 year and 2 years after transplant and once per year thereafter. At the same timepoints, the 
ratio of donor-derived cells to recipient-derived bone marrow cells, peripheral blood cells, and T 
lymphocytes (chimerism) was evaluated by molecular analysis of short tandem repeats on DNA 
isolated from bone marrow and peripheral blood mononuclear cells. The analysis of the chimeric 
status of peripheral blood T lymphocytes was done after positive selection of CD3-positive cells 
sorted by the AutoMacs device (Miltenyi Biotec, Bergisch Gladbach, Germany). The achievement 
of a full haemopoietic donor chimerism (defined as more than 95% of cells being of donor origin) 
was evaluated on bone marrow cells, peripheral blood cells and T lymphocytes at 30, 60, 100, 180 
days and 1 year after transplant. Acute graft-versus-host disease with organ involvement and 
symptoms was assessed on a weekly basis for the first 3 months after transplant and graded 
according to the Glucksberg scale. Chronic graft-versus-host disease was assessed at each follow-up 
visit and classified as limited or extensive. 
Outcomes 
The primary endpoint was the cumulative incidence of non-relapse mortality, assessed at 1 year 
after transplantation. Non-relapse mortality was defined as death from any cause not subsequent to 
relapse. Secondary endpoints for efficacy and safety were cumulative incidence of relapse, 
leukaemia-free survival, and overall survival at 1 and 2 years after transplantation, neutrophil and 
platelet engraftment, haemopoietic chimerism, incidence of rejection and graft failures, incidence of 
acute and chronic graft-versus-host disease, and cumulative incidence of regimen-related toxic 
effects, according to Bearman's criteria,
18
 and are described further in the appendix. Deaths after 
relapse were categorised as caused by the disease irrespective of the proximate cause. 
Haematological relapse was defined via cytological assessment of the bone marrow. Neutrophil 
engraftment was defined as the number of days after transplantation taken to achieve an absolute 
neutrophil count of at least 0·5 × 109 cells per L and platelet engraftment was defined as the number 
of days to maintain an untransfused platelet count of at least 20·0 × 109 cells per L. Graft failure was 
defined as the absence of donor cells in the bone marrow by day 30 after transplant. Graft rejection 
was defined as the absence of donor cells in the bone marrow by day 60 after transplant following 
an initial haemopoietic chimerism. Adverse events were recorded in accordance with the Medical 
Dictionary for Regulatory Activities (MedDRA) version 10.0 code and graded with the National 
Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. 
Statistical analysis 
We calculated the necessary sample size by assuming that 1-year non-relapse mortality in the 
busulfan plus cyclophosphamide group would be 25% (range 16–50). To show a reduction in non-
relapse mortality of 50% to 12·5% (range 0–30) in the busulfan plus fludarabine group, 240 patients 
needed to be enrolled and randomly assigned (120 patients in each group) for a power of 80% (type 
II error 0·2). We used a two-sided alpha-level probability of 0·05 (type I error). 
We used χ2 tests or Fisher's exact test to assess categorical variables. Non-relapse mortality and the 
incidence of relapse incidence were considered to be competing events and we assessed group 
differences using the Fine and Gray's non-parametric test.
19
 We calculated leukaemia-free survival 
and overall survival using the Kaplan-Meier method and we made comparisons by the log-rank test 
using censored data. We assessed the effect of treatment on non-relapse mortality and cumulative 
incidence of relapse at 1 year in prespecified subgroups by fitting a Cox model and calculating 
cause-specific HRs and 95% CIs. We assessed the effect of treatment on non-relapse mortality and 
cumulative incidence of relapse at 1 year in prespecified subgroups by fitting a Cox model and 
calculating HRs and 95% CIs. We did multivariable analyses at the two-tailed 5% significance level 
and calculated adjusted hazard ratios (HRs) and 95% CIs by fitting Cox models. Non-relapse 
mortality, cumulative incidence of relapse, leukaemia-free survival, and overall survival were 
analysed on an intention-to-treat basis. The subgroup analysis, multivariable analysis, and safety 
assessments were done in the per-protocol population. All reported p values are two-sided. 
One interim analysis was done after half of the patients (n=120) had been accrued, mainly to assess 
severe adverse effects, which could affect the continuation of the trial, but also to provide a first 
efficacy profile with an assessment of the adequacy of the sample size calculation. The numbers of 
treatment failures and serious adverse events were closely monitored by the Data Safety Monitoring 
Board for unexpected trends. All analyses were done with SAS version 9.3 and R version 3.1.2 
software. 
This trial is registered with ClinicalTrials.gov, number NCT01191957. 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The Steering Committee delegated the Fondazione Mario 
Negri Sud as the core data management and statistical facility, which did the centralised data 
collection, Good Clinical Practice quality monitoring, and analysis of data. The corresponding 
author (AR) and AM, CB, EO, and RMM had full access to all the data in the study and AR had 
final responsibility for the decision to submit for publication. 
Results 
From Jan 3, 2008, to Dec 20, 2012, we enrolled 252 patients and randomly assigned them to receive 
busulfan plus cyclophosphamide (n=125) or busulfan plus fludarabine (n=127). Four patients had a 
leukaemia relapse before conditioning (three died subsequently and one received a transplant 
outside the protocol) and three patients withdrew consent (figure 1). The allocated treatment was 
delivered to 121 patients in the standard busulfan plus cyclophosphamide group and 124 in the 
experimental busulfan plus fludarabine group; patients in this per-protocol population were treated 
with no deviations from the scheduled time and dose administration defined by the study protocol. 
The main clinical features were balanced between the groups (table 1). Fewer patients with a 
Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score
20
 of 1–2, and 
more patients with a score of 3 or more, were allocated to the busulfan plus fludarabine group than 
to the busulfan plus cyclophosphamide group. 
 
Figure 1. Trial profile 
 
Table 1. Baseline demographic and transplant characteristics 
 
 Data are n (%) or median (IQR). ELN=European Leukemia Network. HCT-
CI=Hematopoietic Cell Transplantation-Specific Comorbidity Index. 
* 
Patients not undergoing allogeneic stem-cell transplantation. 
Median follow-up was 27·5 months (IQR 9·8–44·3). At 1 year, overall non-relapse mortality in the 
busulfan plus cyclophosphamide group was 17·2% (95% CI 11·6–25·4) compared with 7·9% (4·3–
14·3) in the busulfan plus fludarabine group (Gray's test p=0·026; figure 2). At 1 year, non-relapse 
death occurred in 21 patients in the busulfan plus cyclophosphamide group and 10 patients in the 
busulfan plus fludarabine group. At 2 years, non-relapse mortality in the busulfan plus 
cyclophosphamide group was 18·0% (12·3–26·4) versus 9·5% (5·5–16·3) in the busulfan plus 
fludarabine group, and at 5 years this was 19·0% (13·1–27·5) in the busulfan plus 
cyclophosphamide group versus 10·6% (6·3–17·8) in the busulfan plus fludarabine group (Gray's 
test p=0·047 at 2 years and p=0·050 at 5 years; figure 2). At 1 year, the cumulative incidence of 
relapse was 22·1% (95% CI 15·8–30·9) in the busulfan plus cyclophosphamide group and 25·2% 
(18·6–34·1) in the busulfan plus fludarabine group (Gray's test p=0·47; figure 2). In both groups, the 
cumulative incidence of relapse remained similar at 2 years (29·6% [22·4–39·0] in the busulfan plus 
cyclophosphamide group vs 31·6% [24·4–40·9] in the busulfan plus fludarabine group; Gray's test 
p=0·59) and 5 years (38·1% [29·7–48·8] in the busulfan plus cyclophosphamide group vs 37·6% 
[29·7–47·4] in the busulfan plus fludarabine group; Gray's test p=0·70; figure 2). All causes of death 
are reported in table 2. 
 
Figure 2. Cumulative incidence of non-relapse mortality (A) and cumulative incidence of relapse 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Causes of death 
 
Data are n (%) for per-protocol population. Comparisons between groups were done with χ2 
tests or Fisher's exact test as appropriate. 
Leukaemia-free survival for busulfan plus cyclophosphamide versus busulfan plus fludarabine was 
60·7% (95% CI 52·6–70) versus 66·9% (59·2–75·6) at 1 year (p=0·38), 52·4% (44·3–62·1) versus 
58·9% (50·9–68·2) at 2 years (p=0·36), and 42·9% (34·4–53·6) versus 51·8% (43·6–61·7) at 5 years 
(p=0·29; figure 3). Relapses occurred in 43 patients in the busulfan plus cyclophosphamide group 
and in 46 patients in the busulfan plus fludarabine group. The proportion of patients who survived 
after relapse was significantly higher in the busulfan plus cyclophosphamide group (16 [35%]) than 
in the busulfan plus fludarabine group (six [13%]; p=0·0083). Overall survival was similar between 
the busulfan plus cyclophosphamide group and the busulfan plus fludarabine group at 1 year 
(71·7% [64·1–80·2] vs 77·0% [70·0–84·7]; p=0·36), 2 years (64·2% [56·1–73·4] vs 62·4% [54·5–
71·5]; p=0·99]) and 5 years (54·8% [45·5–66·0] vs 55·2% [46·7–65·4]; p=0·89; figure 3). In our 
Kaplan Meier analysis, HR was 0·83 (0·58–1·17) for leukaemia-free survival and 0·97 (0·66–1·43) 
for overall survival. 
 Figure 3. Kaplan-Meier curves of leukaemia-free survival (A) and overall survival (B) 
Consistent with results in the intention-to-treat population, in the per-protocol population, non-
relapse mortality was improved for all subgroups of patients given busulfan plus fludarabine, 
compared with patients given busulfan plus cyclophosphamide, while subgroups of patients treated 
with either conditioning regimen had a similar cumulative incidence of relapse (figure 4). The 
prognostic effect of the conditioning regimen and all baseline characteristics on non-relapse 
mortality, cumulative incidence of relapse, leukaemia-free survival, and overall survival was 
assessed in the per-protocol population at 1 year after transplantation (table 3). By univariate 
analysis (data not shown) and multivariate analysis, disease status at transplant was the only factor 
that significantly affected 1-year cumulative incidence of relapse, overall survival, and leukaemia-
free survival, whereas the conditioning regimen was the only factor that significantly affected non-
relapse mortality at 1 year (table 3). 
 
 
Figure 4. Non-relapse mortality and cumulative incidence of relapse at 1 year after transplantation 
HRs and 95% CIs are calculated from Cox regression models. The dotted line represents the point 
estimated for non-relapse mortality and cumulative incidence of relapse for the per-protocol 
population. HR=hazard ratio. ELN=European Leukaemia Network. HCT-CI=Hematopoietic Cell 
Transplantation-Specific Comorbidity Index. 
 
 
 
Table 3. Prognostic factors for outcomes at 1 year after transplantation 
 
Baseline characteristics that are not included in this table were analysed only in univariate analysis. 
HR=hazard ratio. ELN=European Leukemia Network. HCT-CI=Hematopoietic Cell 
Transplantation-Specific Comorbidity Index. 
Median time to neutrophil engraftment was 16 days (IQR 14–18) in the busulfan plus 
cyclophosphamide group and 17 days (15–20) in the busulfan plus fludarabine group (Gray's test 
p=0·55). Median time to platelet engraftment was 20 days (15–25) for patients given busulfan plus 
cyclophosphamide and 17 days (14–21) for patients given busulfan plus fludarabine (Gray's test 
p=0·002; appendix). Two graft failures and two graft rejections occurred in patients receiving 
busulfan plus cyclophosphamide, whereas one graft rejection occurred in the busulfan plus 
fludarabine group. No difference in haemopoietic chimerism existed between unfractionated 
mononuclear cells obtained from bone marrow and peripheral blood in either treatment group. 
However, when we compared the haemopoietic chimerism of purified peripheral blood T 
lymphocytes at early timepoints (days 30 and 60), full donor chimerism was significantly higher in 
the busulfan plus cyclophosphamide group (30/36 [83%] at 30 days; 29/36 [81%] at 60 days) than 
in the busulfan plus fludarabine group (16/38 [42%] at 30 days, p=0·00026; 23/40 [58%] at 60 days, 
p=0·031). A progressive increase in T-lymphocyte donor chimerism gradually developed at later 
timepoints in the busulfan plus fludarabine group, at days 100, 180, and 365 after transplantation 
(appendix). Despite the early delay in the achievement of full donor T lymphocyte chimerism in the 
busulfan plus fludarabine group, the number of donor lymphocyte infusions was not different 
between study groups (18 in the busulfan plus cyclophosphamide group vs 14 in the busulfan plus 
fludarabine group, χ2 p=0·41). 
At least one grade 3 or worse adverse event was reported for 62 (51%) of 121 patients in the 
busulfan plus cyclophosphamide group and 46 (37%) of 124 patients in the busulfan plus 
fludarabine group (table 4). The most frequently reported grade 3 or higher adverse events were 
gastrointestinal events (28 [23%] patients in the busulfan plus cyclophosphamide group vs 26 [21%] 
patients in the busulfan plus fludarabine group) and infections (21 [17%] patients in the busulfan 
plus cyclophosphamide group and 13 [10%] patients in the busulfan plus fludarabine group had at 
least one such event). Adverse events with an outcome of death were reported for 19 (16%) patients 
in the busulfan plus cyclophosphamide group and 10 (8%) in the busulfan plus fludarabine group. 
Eight secondary malignancies were diagnosed in six patients, all of whom received busulfan plus 
fludarabine ( table 4). The most common conditioning regimen-related toxic effects assessed shortly 
(within 28 days) after transplantation are shown in table 5. Four patients (two in each treatment 
group) had a diagnosis of venous occlusive disease. The 100-day cumulative incidence of grade II–
IV acute graft-versus-host disease was 28·1% (95% CI 21·1–37·4) in the busulfan plus 
cyclophosphamide group versus 19·4% (13·5–27·8) in the busulfan plus fludarabine group (Gray's 
test p=0·12), whereas grade III–IV acute graft-versus-host disease was significantly more common 
in the busulfan plus cyclophosphamide group (12 [10%] patients) than in the busulfan plus 
fludarabine group (three [2%] patients; Gray's test p=0·014; appendix). At 1 year, the cumulative 
incidence of chronic graft-versus-host disease was 27·5% (20·6–36·9) in the busulfan plus 
cyclophosphamide group and 25·8% (19·1–34·8) in the busulfan plus fludarabine group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Adverse events 
 
Data are number of patients (%). 
* 
Includes general symptoms of fever, fatigue, and insomnia. Only grade 1–2 adverse events 
that occurred in more than 10% of patients in any group are reported, whereas all grade 3, 4, 
and 5 adverse events that occurred after treatment allocation are reported. 
Table 5. Regimen-related toxic effects by organ system within 28 days after 
transplantation in the per-protocol population 
 
Data are number of patients (%). Toxic effects were judged with Bearman's criteria.18 
Discussion 
In this study, the combination of busulfan plus fludarabine, compared with busulfan plus 
cyclophosphamide, was associated with significantly lower non-relapse mortality for older (median 
age 51 years) patients with acute myeloid leukaemia who underwent allogeneic haemopoietic stem-
cell transplant from an HLA-matched related or unrelated donor. Non-relapse mortality in patients 
receiving the busulfan plus fludarabine regimen was lower in all subgroups analysed compared with 
that for patients in the busulfan plus cyclophosphamide group, especially for patients in their first 
complete remission and in those with an HCT-CI of 3 or greater, and was independent of patient 
age and sex, donor type, graft type, and acute myeloid leukaemia risk biology. Chemotherapy-
related organ toxic effects were less common in patients treated with the busulfan plus fludarabine 
regimen than those treated with the busulfan plus cyclophosphamide conditioning; the primary 
endpoint of the study was probably met because of the reduced organ toxicity of the busulfan plus 
fludarabine regimen. Fludarabine has been postulated to be associated with reduced toxic effects in 
several organs, including the heart, lungs, and liver, while the myeloablative dose of busulfan was 
predicted to preserve the antileukaemic effect of the regimen. Most importantly, the reduced non-
relapse mortality did not come at the cost of a significantly increased incidence of relapse, which 
was similar between the busulfan plus fludarabine and busulfan plus cyclophosphamide groups, 
both overall and in subgroup analysis. 
Our results concur with those reported in other clinical trials. In a phase 2 study,
21
 patients aged 50–
70 years were given transplants for myeloid malignancies after a busulfan plus fludarabine 
myeloablative conditioning regimen. For patients in complete remission at the time of the 
transplant, 1-year transplant-related mortality was 19%, with a 2-year event-free survival of 71% 
and an overall survival of 68%. Additionally, in a randomised clinical trial
17
 done in younger 
(median age of 30 years) patients with acute myeloid leukaemia, non-relapse mortality at 5 years 
was lower in patients treated with busulfan plus fludarabine (10%) compared with those given 
busulfan plus cyclophosphamide (19%). As in our study, the overall incidence of relapse was 
superimposable between the study groups and, although not significant, the patients who received 
fludarabine had improved disease-free survival and overall survival compared with those who 
received cyclophosphamide. 
The lower non-relapse mortality at 1 year in favour of the busulfan plus fludarabine group was 
maintained up to 5 years. Therefore, the reduction of the antileukaemic power of a conditioning 
regimen should be carefully assessed for patients with acute myeloid leukaemia up to the age of 65 
years. Notably, the lower transplant-related mortality is not a consequence of poor performance in 
the control group. In fact, the busulfan plus cyclophosphamide regimen was better tolerated than 
initially postulated when the trial was designed and non-relapse mortality in this group was similar 
to that reported in large international non-randomised studies
4, 5 and 6
 that were done in patients of 
similar or younger median age with myeloid malignancies. The overall good performance of both 
treatment groups is emphasised by three further findings. First, most patients had intermediate-risk 
or high-risk acute myeloid leukaemia and only six patients with a favourable cytogenetic profile had 
received transplants in their first remission. In this respect, our results are similar to those reported 
in a comparable set of older patients with acute myeloid leukaemia who were enrolled into studies 
in the HOVON-SAKK analysis.
22
 Second, patients receiving transplants from related or unrelated 
donors were equally represented in both treatment groups and no difference existed in the treatment 
outcome according to stem cell source or donor type. Our results also support the notion that 
transplantations from matched related donors and matched unrelated donors produce similar 
outcomes for patients with acute myeloid leukaemia.
23
 All transplants from unrelated donors in our 
study included an intermediate dose of antithymocyte immunoglobulin as part of the conditioning 
regimen and this did not translate into any significant increase of relapse or transplant-related 
complications. Third, the incidence of venous occlusive disease was very low in both treatment 
arms: the reduction of this life-threatening complication is probably related to the use of an 
intravenous formulation of busulfan.
24
 Importantly, after busulfan plus fludarabine was given to 
patients, the speed and robustness of haematological engraftment was similar to, if not better than, 
that observed in the control group, despite the fact that full T-cell engraftment was delayed. This 
finding did not translate into an increase in early or late graft failures and we speculate that the 
significantly reduced incidence of grade III–IV acute graft-versus-host disease reported in the 
busulfan plus fludarabine group might be at least partly related to the kinetics of T-cell 
reconstitution in this group. 
Several studies
25, 26 and 27
 have reported that reduction of the myeloablative component of 
chemotherapy-based conditioning regimens is associated with a significant increase in relapse 
incidence, although in a recent randomised trial,
28
 no difference in relapse was detected in a 
comparison of total body irradiation-based conditioning regimens (8 Gy vs 12 Gy) for patients with 
acute myeloid leukaemia. A phase 3 study (ClinicalTrials.gov, number NCT01339910) by the Bone 
Marrow Transplant Clinical Trials network to compare myeloablative conditioning with reduced 
intensity conditioning in patients with acute myeloid leukaemia and myelodysplastic syndrome, 
aged 18–65 years, was closed prematurely because of an excess of relapse in the reduced intensity 
programme. 
Our results contrast with those published by Lee and colleagues
16
 who compared a busulfan plus 
fludarabine conditioning regimen with busulfan plus cyclophosphamide in 126 younger adults 
(median age 41 years) eligible for myeloablative conditioning. Although severe (grade 3 or higher) 
infection and gastrointestinal adverse events were significantly more common in the busulfan plus 
cyclophosphamide group, the frequency of hepatic adverse events was similar between the two 
groups. Moreover, overall non-relapse mortality was similar between the two groups and the 
busulfan plus cyclophosphamide group had improved 2-year overall survival and event-free 
survival compared with the busulfan plus fludarabine group. Beyond the substantial difference in 
the median age of the patients in this study and ours, we must emphasise the fact that Lee and 
colleagues' study had a smaller number of patients and seemed to lack a formal sample size 
calculation. Furthermore, only 70 of 126 patients in that study had a diagnosis of acute myeloid 
leukaemia. 
Our study has several limitations that should be taken into consideration. Most patients were in their 
first complete remission and it is possible that before being randomly assigned to a myeloablative 
conditioning regimen they had been selected for enrolment on the basis of a favourable HCT-CI 
score and good performance status.
29
 Accordingly, the generalisability of our results should be 
critically assessed when decisions are made about the conditioning regimen for older patients with 
acute myeloid leukaemia, especially when severe comorbidities or poor performance status are 
present. Additionally, we recognise that for patients who relapse after transplantation, the outcome 
was better in the busulfan plus cyclophosphamide group than in the busulfan plus fludarabine 
group. The reduced success of the rescue treatment for disease relapse after busulfan plus 
fludarabine treatment might be a matter of chance, but alternative explanations include the possible 
selection of more aggressive leukaemic cell clones that have survived a purine analogue-containing 
chemotherapy and the increased incidence of infectious complications. Finally, although non-
relapse mortality was lower in the busulfan plus fludarabine group than in the busulfan plus 
cyclophosphamide group, overall survival was not different between the groups, which emphasises 
the fact that leukaemia relapse after transplantation remains an unmet clinical need for patients with 
acute myeloid leukaemia. For this reason, innovative post-engraftment treatments with cells or 
drugs should now be regarded as an integral part of the allogeneic stem-cell transplantation 
platform, and clinical trials that have been appropriately designed to address the efficacy and toxic 
effects of such new approaches are needed.
30
 
Our results support myeloablative busulfan plus fludarabine as a highly effective conditioning 
regimen for patients aged 40–65 years with acute myeloid leukaemia, conferring lower transplant-
related mortality than with standard treatment. These results might be useful in the planning of 
allogeneic transplants for older patients with acute myeloid leukaemia. 
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